Monthly Archives: November 2010

CI & Patent News: 20/11/2010

1) GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases (Press Release) … This new collaborative framework, builds on a long-standing relationship between Fiocruz and GlaxoSmithKline, established in 1985, to manufacture vaccines for public … Continue reading

Posted in Daily interesting IP news | Tagged , , , , , | Leave a comment

Modafinil Cephalon Vs Orchid & Mylan (UK Case)

Yesterday high court of London has denied to grant interim injunction on Mylan marketing generic version of Modafinil (provigil) in UK. The final trial is pending on April 2011 (on expedite basis) (order) The Case was about whether Orchid’s API … Continue reading

Posted in Patent case | Tagged , , | Leave a comment

Hepatitis C Cont…(3)

(Post 1) (Post 2) (Post 3) Medivir is also developing Hepatitis C drug (TMC435) with Tibotec Pharmaceuticals. Medivir announced positive interim Phase IIb data on efficacy of TMC 435. (Bloomberg) TMC435 is a once daily protease inhibitor jointly developed by … Continue reading

Posted in Drug developments & targets | Leave a comment

Darunavir Paragraph IV litigation

Tibotec, on Nov 15th 2010, has sued Lupin and Mylan on 7,700,645 patent which expires on Dec 2026. 7,700,645: html | pdf Pseudopolymorphic forms of a HIV protease inhibitor by Vermeersch et. al.; USPC #514/456; It is not sure who is First to file … Continue reading

Posted in Patent case | Leave a comment

CI & Patent News: 18/11/2010

1) Pfizer to market off-patent medicines in Philippines. Pfizer Parke Davis, a new unit will be launching nine generic medicines in Anti-infective, Hypertension and vertigo. (Philstar) 2) Zafirlukast: DRL ANDA does not infringe Astrazeneca’s asserted patents (law360). Paroduct and MOT … Continue reading

Posted in Daily interesting IP news | Leave a comment

Study: CETP inhibitors

Cholesteryl ester transfer protein (CETP) inhibitors are new class of drugs to treat cardiovascular diseases, specifically CETP inhibitors improves high-density lipoproteins (HDL) level in blood. Research of CETP inhibitors might have started somewhere around 1990 to 1995 and PD 140195 … Continue reading

Posted in Drug developments & targets | Leave a comment

CI & patent News: 16/11/2010

1) Zydus enters marketing and supply agreement with Amarillo Biosciences for maxisal. Maxisal is dietary supplement supplied as lozenge contains anhydrous crystalline maltose for the treatment of dry mouth. Zydus will market Maxisal in india and Nepal. Maxisal will improve the … Continue reading

Posted in Daily interesting IP news | Leave a comment

Watson Labs Rosuvastatin Zinc 505(b)(2)

On Oct 27, 2010, Watson confirmed the patent challenge on Rosuvastatin (Astrazeneca sued watson at Delaware). Watson has submitted new drug application under Section 505(b)(2) seeking approval to market rosuvastatin zinc 5, 10, 20 and 40 mg tablets (press release). On Nov … Continue reading

Posted in Daily interesting IP news, Patent case | Leave a comment

CI and Patent News: 13/11/2010

1) Forest Laboratories, Inc today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, … Continue reading

Posted in Daily interesting IP news | Leave a comment

CI and Patent news: 10/11/2010

1) Paragraph IV Litigations (priorsmart.com) 1) Dasatinib (Bristol Myers Squibb Vs Apotex) filed on Nov. 8, 2010 in the U.S. District Court for the District of New Jersey; View on PriorSmart Patents in suit: 7,125,875;  6,596,746; 7,491,725; 7,153,856 Apotex may be first … Continue reading

Posted in Daily interesting IP news | Leave a comment